StemCell Therapy

HONG KONG, June 11, 2012 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its preliminary unaudited financial results for the fourth quarter and fiscal year ended March 31, 2012.

Fourth Quarter of Fiscal 2012 Highlights

Full Year of Fiscal 2012 Highlights

"We are pleased by our accomplishments in fiscal year 2012 on several fronts," stated Ms. Ting Zheng, Chairperson and Chief Executive Officer of China Cord Blood Corporation. "For the full year, we exceeded our target of 50,000 new subscribers to add total of 53,924 new subscribers, expanding our total accumulated subscriber base to nearly 240,000. Such growth speaks well for our new marketing strategy, which targets high-end subscribers by offering premium services, and the well-received reception by the market."

"Furthermore, our new payment model with its emphasis on upfront payments and a higher processing fee per subscriber has strengthened our financial performance," continued Ms. Zheng. "The market's acceptance of this new payment model reinforces our conviction that we have developed a strong foundation for the Company's brand in each region upon which we are successfully expanding China Cord Blood's footprint. In addition to enhancing our strategic positioning, the new payment model has also strengthened our cash flow position as cash generated from operating activities almost doubled in fiscal 2012 from the prior year. All in all, fiscal 2012 concluded with the Company in an outstanding financial position and represented a successful first step towards repositioning our company as a premium healthcare service provider with recognized high-quality services."

Summary The Fourth Quarter and Full Year Ended March 31, 2011 and 2012

Three Months Ended

Twelve Months Ended

March 31,

March 31,

View post:
China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012

This entry was posted on June 12, 2012 at 5:13 am and is filed under Stem Cell Negative. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |